Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC).

Frankie Ann Holmes,Melissa Brammer,Renard Dubois,Feng Xu,Bin. Yao,Deepa Lalla

Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC).

2019

Frankie Ann Holmes
Melissa Brammer
Renard Dubois
Feng Xu
Bin. Yao
Deepa Lalla

e12037Background: Disease-free survival (DFS) in patients with EBC has improved over time. Trials of systemic agents for adj rx of HER2+ BC, including chemotherapies (CT), endocrine, and HER2-targe...

Keywords:

Endocrine system
Drug
Adjuvant therapy
Pathology
Oncology
Breast cancer
Internal medicine
Medicine
in patient
early breast cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations